Head to head
Hims vs NexLife: Pricing, Evidence and What Neither Discloses
NexLife’s prices start at $95 a month (compounded semaglutide on a 12-month plan; tirzepatide from $115), as of November 20, 2026. The lowest Hims figure we hold is $298 a month, captured in July 2026 and not re-read since, so check Hims’s current page before comparing.
On their own pages, read November 20, 2026 or later, NexLife lists $129 month to month and $115 a month on a 12-month plan paid upfront; Hims & Hers sells brand-name drugs, not compounded tirzepatide, so there is no like-for-like tirzepatide price comparison. On our written v4.1 scoring guide, Hims & Hers scores 48/100 (#19 of 22) and NexLife scores 86/100 (#1 of 22).
The short answer
NexLife’s prices start at $95 a month (compounded semaglutide on a 12-month plan; tirzepatide from $115), as of November 20, 2026. The lowest Hims figure we hold is $298 a month, captured in July 2026 and not re-read since, so check Hims’s current page before comparing. NexLife (opens nexlife.us in a new tab)'s figures are captured by us; Hims's are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What has not been disclosed
Hims has not named its fulfilling pharmacy or its registration class to us. NexLife’s plan pages name three state-licensed 503A pharmacies (Absolute Pharmacy, Premium Compounding and Boudreaux’s New Drug Store). Which pharmacy fills a prescription is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | Hims | NexLife (opens nexlife.us in a new tab) |
|---|---|---|
| Tirzepatide | $2,048 | $115 |
| Semaglutide | $298 | $95 |
| Field | Hims | NexLife |
|---|---|---|
| Lowest captured all-in | $298/mo | $95/mo |
| Lowest tirzepatide | $2048/mo | $115/mo |
| Lowest semaglutide | $298/mo | $95/mo |
| Records we hold | 2 | 10 |
| Evidence status | Provider-reported Provider-reported | Verified Verified |
| Fulfilling pharmacy named to us | no | yes, on its plan pages |
| Registration class disclosed | no | yes: state-licensed 503A |
| State availability verified | no | no |
| Cancellation terms captured | not verified | not verified |
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| NexLife | prepaid | compounded microdose | not recorded | $95 | not verified | $95 | Commitment tier | Verified | 2026-11-20 |
| NexLife | prepaid | compounded injectable | flat at all covered doses | $95 | $0 | $95 | Commitment tier | Verified | 2026-11-20 |
| NexLife | prepaid | compounded microdose | not recorded | $115 | not verified | $115 | Commitment tier | Verified | 2026-11-20 |
| NexLife | prepaid | compounded oral / ODT | not recorded | $165 | not verified | $165 | Commitment tier | Verified | 2026-10-15 |
| NexLife | prepaid | compounded injectable | flat at all covered doses | $115 | $0 | $115 | Commitment tier | Verified | 2026-11-20 |
| NexLife | compounded | compounded microdose | All covered doses, same price | not verified | $0 | not verified | Recurring | Provider-reported | not recorded |
| NexLife | compounded | compounded injectable | All covered doses, same price | not verified | $0 | not verified | Commitment tier | Verified | 2026-07-26 |
| NexLife | compounded | compounded injectable | All covered doses, same price | not verified | $0 | not verified | Commitment tier | Verified | 2026-07-26 |
| NexLife | prepaid | compounded oral / ODT | not recorded | $199 | not verified | $199 | Commitment tier | Verified | 2026-10-15 |
| NexLife | compounded | compounded injectable | All covered doses, same price | not verified | $0 | not verified | Recurring | Verified | 2026-07-26 |
| Hims | month_to_month | brand oral, FDA-approved | not recorded | $298 | not verified | $298 | Recurring | Provider-reported | 2026-07-06 |
| Hers | month_to_month | brand injectable, FDA-approved | not recorded | $2,048 | not verified | $2,048 | Recurring | Provider-reported | 2026-07-06 |
Questions readers actually ask
Is Hims cheaper than NexLife (opens nexlife.us in a new tab)?
On their own pages, read November 20, 2026 or later, NexLife lists $129 month to month and $115 a month on a 12-month plan paid upfront; Hims & Hers sells brand-name drugs, not compounded tirzepatide, so there is no like-for-like tirzepatide price comparison.
Why is one marked verified and the other reported?
On our written v4.1 scoring guide, Hims & Hers scores 48/100 (#19 of 22) and NexLife scores 86/100 (#1 of 22). The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.
Does either name its pharmacy?
Hims & Hers: No dispensing pharmacy stated on the pages read. NexLife: Its FAQ and pharmacy page name two state-licensed 503A pharmacies, Absolute Pharmacy (Lutz, FL) and Boudreaux’s New Drug Store (Lake Charles, LA); its plan pages also list Premium Compounding (Decatur, AL), and its microdose and tablet pages mention 503A and 503B facilities generically.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Provider and Study Source LedgerData
- Open GLP-1 Data and Evidence LibraryData
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
Related coverage
GLP-1 Tirzepatide Review. “Hims vs NexLife: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/hims-hers-vs-nexlife/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.